Qiao, N., Insinga, R., de Lima Lopes Junior, G., Cook, J. and Sénécal, M. (2021) A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-Small Cell Lung Cancer. PharmacoEconomics Open, 5, 365-383.
https://doi.org/10.1007/s41669-020-00255-2

has been cited by the following article:

• TITLE: Non-Small Cell Lung Cancer: Treatment, Diagnosis, and Life after Treatment

  AUTHORS: Reethi Yadlapalli, Eswar Kumar Adoni Valmiki, Terry Oroszi

  KEYWORDS: Treatment, Lung Cancer, Non-Small Cell Lung Cancer, Diagnosis

  JOURNAL NAME: Journal of Cancer Therapy, Vol.13 No.7, July 18, 2022

  ABSTRACT: Lung cancer is becoming the most common cancer globally. In China, Lung cancer has become prevalent among preceding compared to present smokers. There are many treatments for lung cancer globally like Chemotherapy, Radiotherapy, Surgery, and Targeted therapy [1] [2]. Generally, lung cancer starts in the lungs. The spongy lungs in the chest inhale oxygen and exhale carbon dioxide. Those who smoke regularly have the highest risk of lung cancer than nonsmokers. This risk increases with an increase in length, time, and the number of cigarettes smoked. Immediate treatment will help in reducing the severity of cancer. The complications of lung cancer include shortness of breath, coughing up blood, pain, and fluid in the chest. Therefore, the primary step in preventing lung cancer is quitting smoking [3].